Volume | 250,484 |
|
|||||
News | - | ||||||
Day High | 15.09 | Low High |
|||||
Day Low | 14.82 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Catalyst Pharmaceuticals Inc | CPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
15.05 | 14.82 | 15.09 | 14.99 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,655 | 250,484 | $ 14.96 | $ 3,746,323 | - | 11.09 - 17.765 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:18:51 | 10 | $ 15.00 | USD |
Catalyst Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.77B | 117.86M | - | 398.2M | 71.41M | 0.61 | 24.77 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Catalyst Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.07 | 15.52 | 14.68 | 14.99 | 1,063,812 | -0.07 | -0.46% |
1 Month | 15.53 | 16.25 | 14.585 | 15.22 | 1,332,672 | -0.53 | -3.41% |
3 Months | 13.32 | 17.495 | 13.125 | 15.47 | 1,338,826 | 1.68 | 12.61% |
6 Months | 13.00 | 17.495 | 12.27 | 14.93 | 1,376,821 | 2.00 | 15.38% |
1 Year | 17.26 | 17.765 | 11.09 | 13.93 | 1,457,913 | -2.26 | -13.09% |
3 Years | 4.67 | 22.11 | 4.43 | 12.48 | 1,617,662 | 10.33 | 221.20% |
5 Years | 3.75 | 22.11 | 2.235 | 8.71 | 1,765,175 | 11.25 | 300.00% |
Catalyst Pharmaceuticals Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |